Oncology Drug Review Process

Authors:
Ann T. Farrell From Division of Oncology Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland.

Search for other papers by Ann T. Farrell in
Current site
Google Scholar
PubMed Close
 MD
and
Richard Pazdur From Division of Oncology Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland.

Search for other papers by Richard Pazdur in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 1: Issue 1
Online Publication Date:
Mar 2003
DOI:
https://doi.org/10.6004/jnccn.2003.0011
Full access

The U.S. Food and Drug Administration facilitates the development of drugs intended to treat cancer and other serious or life-threatening diseases. This article describes the new drug application (NDA) process, endpoints used in oncologic trials, and recent initiatives to expedite the review of drugs used to treat serious and life-threatening diseases. The Food and Drug Administration can grant either regular or accelerated marketing approval for oncology drugs. Regular approval is based on endpoints demonstrating that the drug provides a clinical benefit, such as longer life, enhanced quality of life, or a favorable effect on an established surrogate for longer or better life, such as long-term complete responses. Accelerated approval is based on a surrogate endpoint that is less well established but is reasonably likely to predict a longer or better life and can be granted for drugs that are intended to treat a serious or life-threatening illness and that provide meaningful therapeutic benefit to patients over existing therapies. The Agency classifies an NDA as either a priority or a standard application. Drugs that receive priority review are agents that appear to represent significant improvements over existing therapies. A priority NDA is reviewed by the Agency within 6 months; a standard review is accomplished within 10 months. The Agency communicates with sponsors throughout the drug development process, suggesting appropriate trial designs and meaningful endpoints.

Correspondence: Ann T. Farrell, Division of Oncology Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, United States Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. E-mail: farrella@cder.fda.gov
  • Collapse
  • Expand
  • 1

    21 Code of Federal Regulations, Part 314. Washington, DC: U.S. Government Printing Office.

  • 2

    21 Code of Federal Regulations, Subpart H Part 314.500. Washington, DC: U.S. Government Printing Office.

  • 3

    Guidance for Industry: Fast Track Drug Development Programs: Designation, Development, and Application Review. Washington, DC, United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, September 1998.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    United States Food and Drug Administration: Manual of Policies and Procedures, 6020.3 Priority Review Policy, April 22, 1996. Washington, DC, United States Department of Health and Human Services, Food and Drug Administration, 1996.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Guidance for Industry: Special Protocol Assessment. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, May 2002.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, May 1998.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Williams G, He K, Chen G et al.. Operational Bias in Assessing Time to Progression. Alexandria, VA: 2002 American Society of Clinical Oncology, Abstract 975.

  • 8

    Johnson J, Williams G, Pazdur R. Endpoints for FDA Approval of Oncology Drugs. 2002 American Society of Clinical Oncology, Abstract 1018.

Copyright:
Copyright © 2003 by the National Comprehensive Cancer Network 2003
Page Numbers:
5
Article Category:
Research Article
Received:
03 Sep 2002
Accepted:
25 Sep 2002
Print Publication Date:
01 Mar 2003
Online Publication Date:
Mar 2003
Keywords:
Clinical benefit; new drug application; response rate; surrogate; survival; time to progression
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 66 66 22
PDF Downloads 39 39 2
EPUB Downloads 0 0 0